Adma Biologics (ADMA) Cost of Revenue (2011 - 2026)
Adma Biologics' (ADMA) quarterly Cost of Revenue came in at -$162.2 million in Q4 2025, down 179.55% YoY from $203.9 million in Q4 2024, and down 376.84% on a QoQ basis from $58.6 million in Q3 2025.
Adma Biologics (ADMA) Cost of Revenue (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Cost of Revenue data on file, last reported at -$162.2 million in Q4 2025.
- Quarterly Cost of Revenue fell 179.55% year-over-year to -$162.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$47.6 million (down 117.88% YoY) and the FY2025 annual result came in at $4.8 million, down 97.66% from the prior year.
- Cost of Revenue eased to -$162.2 million in Q4 2025, from $58.6 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $203.9 million in Q4 2024 to a low of -$162.2 million in Q4 2025.
- A 5-year average of $22.1 million and a median of $3.0 million in 2021 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2021 — Cost of Revenue tumbled 333.42% — and 2024, when it jumped 12786.51%.
- Tracing ADMA's Cost of Revenue over 5 years: stood at -$44.6 million in 2021, then soared by 180.26% to $35.8 million in 2022, then surged by 362.76% to $165.7 million in 2023, then grew by 23.08% to $203.9 million in 2024, then sank by 179.55% to -$162.2 million in 2025.
- The last three Cost of Revenue figures came in at -$162.2 million (Q4 2025), $58.6 million (Q3 2025), and $54.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 38.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.12 Mn |
| Jun 30, 2026 | 38.12 Mn |
| Dec 31, 2025 | -162.23 Mn |
| Dec 31, 2025 | -162.23 Mn |
| Sep 30, 2025 | 58.60 Mn |
| Sep 30, 2025 | 58.60 Mn |
| Jun 30, 2025 | 54.76 Mn |
| Jun 30, 2025 | 54.76 Mn |
| Mar 31, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 203.93 Mn |
| Dec 31, 2024 | 203.93 Mn |
| Sep 30, 2024 | 60.18 Mn |
| Sep 30, 2024 | 60.18 Mn |
| Jun 30, 2024 | 942,000.00 |
| Jun 30, 2024 | 942,000.00 |
| Mar 31, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 165.69 Mn |
| Dec 31, 2023 | 165.69 Mn |